ÂÜÀòÂÒÂ×

The Scientific Research and Development team at Monopteros Therapeutics is dedicated to advancing innovative therapeutic approaches, focusing on the development and optimization of the MPT-0118 inhibitor. This interdisciplinary team collaborates on drug development, conducts non-clinical safety assessments, and provides scientific guidance to ensure that the clinical trials effectively reprogram regulatory T cells for targeted cancer treatments. Through their expertise in chemistry and research, they aim to propel the company’s first-in-class therapies from conception to clinical application.